Abstract: The disclosure provides recombinant herpes virus with diminished latency. In embodiments, the recombinant herpes virus comprises a latency gene or transcript linked to an altered or heterologous promoter. The disclosure also provides compositions and methods for inducing immunity in animals using the recombinant herpes viruses.
Type:
Application
Filed:
March 11, 2022
Publication date:
June 23, 2022
Applicant:
The U.S.A., as represented by the Secretary, Department of Health and Human Services
Abstract: Human monoclonal antibodies that specifically bind Fms-like tyrosine kinase 3 (FLT3) are described. Chimeric antigen receptors (CARs) and other antibody conjugates that include the FLT3-specific monoclonal antibodies are also described. Methods for the diagnosis and treatment of FLT3-associated cancer, such as acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), are further described.
Type:
Application
Filed:
January 6, 2022
Publication date:
April 28, 2022
Applicant:
The U.S.A., as represented by the Secretary, Department of Health and Human Services
Inventors:
Dimiter S. Dimitrov, Weizao Chen, Terry J. Fry, Christopher Chien
Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus infection in mammals, and methods of using those compositions of matter for the same are disclosed. Also disclosed are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.
Type:
Application
Filed:
December 16, 2021
Publication date:
March 31, 2022
Applicants:
The U.S.A., as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
Wei Bu, Masaru Kanekiyo, Michael Gordon Joyce, Jeffrey I. Cohen
Abstract: Human monoclonal antibodies that specifically bind Ebola virus glycoprotein with nanomolar affinity are described. The monoclonal antibodies were isolated by bulk sorting of plasmablasts from a human Ebola virus vaccinee and pairing of the immunoglobulin heavy and light chain genes using emulsion PCR. The paired immunoglobulin genes were expressed using Fab yeast display to screen and characterize the antibodies. The Ebola virus-specific monoclonal antibodies can be used, for example, to diagnose and treat Ebola virus infection or Ebola virus disease in a subject.
Type:
Application
Filed:
December 19, 2019
Publication date:
March 24, 2022
Applicant:
The U.S.A., as represented by the Secretary, Department of Health and Human Services
Inventors:
Nancy J. Sullivan, John Misasi, Brandon Dekosky, Kendra Elizabeth Leigh
Abstract: Camel single-domain monoclonal antibodies that specifically bind human and mouse mesothelin are described. Chimeric antigen receptor (CAR) T cells and antibody conjugates based on the mesothelin-specific antibodies are also described. The disclosed CAR T cells, mesothelin-specific antibodies and conjugates thereof can be used, for example, in the diagnosis or treatment of mesothelin-positive cancers.
Type:
Application
Filed:
January 2, 2020
Publication date:
March 3, 2022
Applicant:
The U.S.A., as represented by the Secretary, Department of Health and Human Services
Inventors:
Mitchell Ho, Ira H. Pastan, Jessica D. Hong, Nan Li
Abstract: New methods and assays for multiplexed detection of analytes using phosphors that are uniform in morphology, size, and composition based on their unique optical lifetime signatures are described herein. The described assays and methods can be used for imaging or detection of multiple unique chemical or biological markers simultaneously in a single assay readout.
Type:
Application
Filed:
July 7, 2021
Publication date:
February 10, 2022
Applicants:
INTELLIGENT MATERIAL SOLUTIONS, INC., LEIDEN UNIVERSITY MEDICAL CENTER, U.S.A , AS REPRESENTED BY THE SECRETARY, OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
Inventors:
Howard Y. BELL, Joshua E. Collins, Paul L.A.M. Corstjens, Sukwan Handali, Hans J. Tanke
Abstract: A recombinant, attenuated mumps virus is described. The recombinant virus is based on the genotype A Jeryl Lynn vaccine strain, but is modified to express genotype G consensus fusion (F) and hemagglutinin-neuraminidase (HN) proteins. The recombinant virus optionally includes a mutation that prevents expression of viral protein V. The recombinant mumps virus can be used as a vaccine to inhibit mumps virus infection and the development of mumps disease.
Type:
Application
Filed:
December 12, 2019
Publication date:
January 27, 2022
Applicant:
The U.S.A., as represented by the Secretary, Department of Health and Human Services
Inventors:
Steven A. Rubin, Trent J. Bosma, Christian J. Sauder, Tahir H. Malik
Abstract: Nucleic acid constructs encoding a chimeric antigen receptor (CAR) and a truncated human epidermal growth factor receptor (huEGFRt) are described. The encoded CARs include a tumor antigen-specific monoclonal antibody, such as a glypican-3 (GPC3)-specific, a GPC2-specific or a mesothelin-specific monoclonal antibody, fused to a CD8? hinge region, a CD8? transmembrane region, a 4-1BB co-stimulatory domain and a CD3? signaling domain. Isolated host cells, such as isolated T cells that co-express the disclosed CARs and huEGFRt are also described. T cells transduced with the disclosed CAR constructs can be used for cancer immunotherapy.
Type:
Application
Filed:
November 7, 2018
Publication date:
December 2, 2021
Applicant:
The U.S.A., as represented by the Secretary, Department of Health and Human Services
Abstract: Described herein is the discovery that cancer stem cells (CSCs) can be induced to differentiate by altering CD47 signaling. Provided herein are methods and compositions for inducing differentiation of cancer stem cells, for instance irreversible differentiation, including methods of treating subjects with cancer such as breast cancer, colon cancer, lung cancer, ovarian cancer, or melanoma, and including metastatic as well as primary cancer. Also provided are methods for treating subjects with triple negative breast cancers involving forcing differentiation of bCSCs of the subjects through targeting of CD47.
Type:
Application
Filed:
June 14, 2021
Publication date:
November 18, 2021
Applicant:
The U.S.A, as represented by the Secretary, Department of Health and Human Services
Inventors:
David D. Roberts, Sukhbir Kaur, Chengyu Liu
Abstract: Monoclonal antibodies selected from immunized mice, immunized rabbits and a human scFv library that specifically bind fibroblast growth factor receptor 4 (FGFR4) are described. Chimeric antigen receptors, antibody-drug conjugates, immunoconjugates, bispecific antibodies and immunoliposomes comprising the disclosed FGFR4-specific antibodies are also described. The antibody compositions can be used to diagnose or treat a FGFR4-positive cancer, such as rhabdomyosarcoma, lung cancer, liver cancer, breast cancer, pancreatic cancer or prostate cancer.
Type:
Application
Filed:
June 23, 2021
Publication date:
October 21, 2021
Applicant:
The U.S.A., as represented by the Secretary, Department of Health and Human Services
Inventors:
Javed Khan, Sivasubramanian Baskar, Rimas J. Orentas, Dimiter S. Dimitrov, Zhongyu Zhu, Tai Chi Cheuk
Abstract: An affinity matured anti-CD22 human monoclonal antibody exhibiting significantly higher affinity (less than 50 pM) compared to the parental antibody (affinity of about 2 nM) is described. The anti-CD22 variant antibody or a fragment thereof, such as a single-chain variable fragment (scFv), can be used as the antigen-binding portion of chimeric antigen receptors (CARs), antibody-drug conjugates (ADCs), immunotoxins or multi-specific antibodies for the treatment of B-cell malignancies.
Type:
Application
Filed:
July 11, 2019
Publication date:
October 21, 2021
Applicant:
The U.S.A., as represented by the Secretary, Department of Health and Human Services
Inventors:
Dimiter S. Dimitrov, Zhongyu Zhu, Sneha Ramakrishna, Terry J. Fry
Abstract: Chimeric flaviviruses that include non-coding regions, non-structural proteins, a capsid (C) protein and a portion of a premembrane (prM) signal sequence from an attenuated or wild-type dengue serotype 2 virus (DENV-2), and a portion of a prM signal sequence, a prM protein and at least a portion of an envelope (E) protein from a Zika virus (ZIKV) are described. Also described are immunogenic compositions and methods for eliciting an immune response in a subject, such as an immune response directed against ZIKV.
Type:
Application
Filed:
July 6, 2017
Publication date:
September 23, 2021
Applicant:
The U.S.A., as represented by the Secretary, Department of Health and Human Services
Abstract: Monoclonal antibodies that bind glypican-2 (GPC2) with high affinity are described. Immunotoxins and chimeric antigen receptors (CARs) that include the disclosed antibodies or antigen-binding fragments thereof are further described. In some instances, the antibody or antigen-binding fragment is humanized. The disclosed GPC2-specific antibodies and conjugates can be used, for example, for the diagnosis or treatment of GPC2-positive cancers, including neuroblastoma, medulloblastoma and retinoblastoma.
Type:
Application
Filed:
August 6, 2019
Publication date:
September 23, 2021
Applicant:
The U.S.A., as represented by the Secretary, Department of Health and Human Services
Abstract: Magnetic resonance methods comprise tractographically establishing a path along a structure in a specimen and finding a distribution of structure radii or cross-sectional areas along the path. Based on the distribution and the path, end-to-end functional characteristics of the structure are estimated. For example, nerve transit times or distributions of transit times can be estimated for a plurality of nervous system locations such as Brodmann areas. Comparison of estimated transit times or distributions thereof between reference values or other values from the same structure can be used to assess specimen health.
Type:
Application
Filed:
May 3, 2021
Publication date:
September 2, 2021
Applicant:
The U.S.A, as represented by the Secretary, Department of Health and Human Services
Abstract: Chimeric antigen receptors containing CD38 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
Type:
Grant
Filed:
November 27, 2019
Date of Patent:
August 31, 2021
Assignees:
Lentigen Technology, Inc., The U.S.A., as represented by The Secretary, Department of Health and Human Services
Inventors:
Dina Schneider, Rimas J. Orentas, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
Abstract: Methods of identifying a subject with a Filovirus infection are provided herein. In some embodiments, the method comprises contacting a biological sample containing antibodies from the subject with one or more peptides comprising amino acid sequences of selected Filovirus epitopes, detecting the presence or absence of an immune complex of antibodies from the biological sample with the one or more peptides; and wherein the presence of the immune complex identifies the subject as having Filovirus infection and the absence of the immune complex identifies the subject as not having Filovirus infection. Further provided are isolated peptides for use in such methods, as well as a solid support linked to one or more of the disclosed peptides.
Type:
Application
Filed:
January 8, 2021
Publication date:
July 8, 2021
Applicant:
The U.S.A., as represented by the Secretary, Department of Health and Human Services
Abstract: Chimeric antigen receptors containing CD38 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
Type:
Grant
Filed:
November 27, 2019
Date of Patent:
June 29, 2021
Assignees:
Lentigen Technology, Inc., The U.S.A., as represented by The Secretary, Department of Health and Human Services
Inventors:
Dina Schneider, Rimas J. Orentas, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
Abstract: Transcriptional units encoding Zika virus (ZIKV) premembrane (prM) and envelope (E) proteins, which upon translation form Zika virus-like particles (VLPs), are described. Use of the transcriptional units and VLPs in three different ZIKV vaccine platforms is described. Immunoassay-based detection methods using ZIKV VLPs are described for the diagnosis of ZIKV infection.
Type:
Application
Filed:
February 5, 2021
Publication date:
June 24, 2021
Applicant:
The U.S.A., as represented by the Secretary, Department of Health and Human Services
Abstract: Identification of immunodominant Babesia microti antigens using genome-wide immunoscreening is described. Candidate antigens were screened against sera from patients with clinical babesiosis. Also described are diagnostic assays with high sensitivity and specificity for detecting B. microti-specific antibodies in patient samples using the identified immunodominant antigens.
Type:
Application
Filed:
November 1, 2018
Publication date:
June 17, 2021
Applicants:
The U.S.A., as represented by the Secretary, Department of Health and Human Services, Yale University
Inventors:
Sanjai Kumar, Nitin Verma, Ankit Puri, Peter J. Krause
Abstract: Anti-EBV gH antibodies, anti-EBV gL antibodies, anti-EBV gH/gL antibodies, and compositions of matter useful for the detection, diagnosis, prevention, and treatment of Epstein Barr Virus infection in humans, and methods of using those compositions of matter for the same.
Type:
Application
Filed:
May 2, 2019
Publication date:
June 10, 2021
Applicants:
The U.S.A., as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
Masaru Kanekiyo, Michael Gordon Joyce, Wei Bu, Jeffrey I. Cohen, Yaroslav Tsybovsky